Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
暂无分享,去创建一个
A. Lazzarin | A. Antinori | F. Mazzotta | L. Galli | M. Malnati | S. Nozza | M. Ripa | S. Chiappetta | M. Pogliaghi | M. di Pietro | S. Bonora | D. De Battista | M. Zaccarelli | S. Ottou | M. D. Di Pietro
[1] A. Antinori,et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial , 2014, The Lancet.
[2] M. Zazzi,et al. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments. , 2014, AIDS research and human retroviruses.
[3] M. Nelson,et al. Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients , 2014, Journal of acquired immune deficiency syndromes.
[4] V. Calvez,et al. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. , 2013, The Journal of antimicrobial chemotherapy.
[5] D. Kuritzkes,et al. Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study , 2013, Journal of acquired immune deficiency syndromes.
[6] Atsushi Jinno-Oue,et al. CCR6 Functions as a New Coreceptor for Limited Primary Human and Simian Immunodeficiency Viruses , 2013, PloS one.
[7] A. Lazzarin,et al. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. , 2013, Journal of Antimicrobial Chemotherapy.
[8] D. Podzamczer,et al. Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients: Randomized, Open-Label Pilot Study , 2013, Journal of acquired immune deficiency syndromes.
[9] A. Lazzarin,et al. Immune recovery and T cell subset analysis during effective treatment with maraviroc. , 2012, The Journal of antimicrobial chemotherapy.
[10] J. Gathe,et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. , 2012, AIDS research and human retroviruses.
[11] C. Rouzioux,et al. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. , 2012, The Journal of infectious diseases.
[12] J. Ainsworth,et al. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. , 2012, The Journal of antimicrobial chemotherapy.
[13] T. Brown,et al. Bone Turnover, Osteoprotegerin/Rankl and Inflammation with Antiretroviral Initiation: Tenofovir versus Non-Tenofovir Regimens , 2011, Antiviral therapy.
[14] M. Moroni,et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. , 2011, The new microbiologica.
[15] A. Lazzarin,et al. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. , 2011, Journal of acquired immune deficiency syndromes.
[16] A. Lazzarin,et al. Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial , 2011, HIV clinical trials.
[17] G. Fätkenheuer,et al. Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2 , 2010, Journal of acquired immune deficiency syndromes.
[18] Wuyuan Lu,et al. CCR6 ligands inhibit HIV by inducing APOBEC3G. , 2010, Blood.
[19] J. Routy,et al. Peripheral Blood CCR4+CCR6+ and CXCR3+CCR6+ CD4+ T Cells Are Highly Permissive to HIV-1 Infection , 2009, The Journal of Immunology.
[20] T. Rutigliano,et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load , 2008, Nature Protocols.
[21] Adeeba Kamarulzaman,et al. AIDS Res Hum Retroviruses , 2006 .
[22] R. Haubrich,et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. , 2006, The Journal of infectious diseases.
[23] B. Gazzard,et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.
[24] M. Lederman,et al. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. , 2002, Clinical immunology.
[25] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[26] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.